|Articles|May 28, 2009
Novartis buys Ebewe injectables unit
28 May 2009
Advertisement
Novartis AG has agreed to buy Ebewe Pharma's injectables unit for $1.2 billion in an all-cash transaction.
The deal excludes Ebewe's neurological products business but will enable Novartis to add generic cancer drugs to its offerings.
Ebewe, based in Austria, generated EUR 188 million in sales last year and EUR 53 million in operating profit.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
2
Study Claims Ozempic Lowers Biological Age
3
What Makes TrumpRx Different from Other Government-Run Health Programs?
4
ACS Calls Obesity a Condition That Must Be Treated with Medication and Surgery
5
